Welcome to the Save Your Skin Foundation media flashback- your weekly guide to the melanoma landscape, and the activities of the Save Your Skin Foundation! It’s an exciting week for the skin cancer community, with the Post-ASCO 2016 Conference in Munich, Germany and the Summit for Cancer Immunotherapy (Canadian Cancer Immunotherapy Consortium and BioCanRx) in Halifax, Nova Scotia, which Save Your Skin Founder Kathy Barnard opened with a discussion of life “beyond the curve” of melanoma. Keep an eye on our facebook page and twitter for updates on both conferences!
We are also excited to announce that we have been featured in the Summer 2016 issue of Canadian Skin, which includes a profile on the Save Your Skin Foundation and a testimonial from one of our board members, Christian Mosley!
Finally, we are still running our survey on sun safety behaviour, which you can fill out here. We appreciate it!
Here are some links and images we shared with you this week:
– This image from Post-ASCO in Munich, which suggests an alteration to the ABCDE (now the ABCD!) rules of clinical mole recognition:
–This article from Modern Medicine Network outlining the S3 international guidelines for actinic keratosis
–This article from Dermatology News reporting the findings of a study done by the US National Cancer Institute’s Surveillance, Epidemiology, and End Results program (SEER), which “highlight[s] the heavy death toll of thin melanomas”
–This article from Ecancernews reporting the suggested links between immunotherapy drugs, such as ipilimumab and nivolumab, and arthritis
–This News Wire article announcing that Merck has approved Keytruda for the treatment of patients with unresectable or metastatic melanoma that have not been treated with ipilimumab
–This article in Bel Marra Health suggesting that the development of vitiligo may be indicative of immunotherapy response
–This article in Trib Live about awesome Mohs histologist Danielle Deroy Pirain, who had a sunscreen dispenser installed in Mt Lebanon Park, Pennsylvania!
-And this Fierce Medical Devices article about the partnership between Australia’s IBM Research and Melanoma Institute Australia to build on IBM’s MoleMap, which seeks to identify patterns in early stage melanoma
Thank you for reading, be sun safe out there!